Pricing Log in Create free account
Saturday 17 October 2026 Export ELMD’s income statement to Excel — free account

Electromed, Inc.

ELMD Healthcare Medical Devices

Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

27.42 0.61 −2.18%
Market cap
$232.3M
P/E
20.0×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
20.30
Beneish M
−2.20
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.20
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — 1 2 — — — —
Insider Ownership 17.01%

Capital & Financial Ratios $m

Market Cap 232.29
Revenue 73.78
Net Income 11.30
Free Cash Flow 8.37
Net Debt (20.45)
Current Ratio 4.69 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 20.01
Fwd P/E 25.50
P/S ratio 3.07
P/B ratio 4.20
Past 5Y EPS Growth 36.94% (at or above 15%: strong)
This Y EPS Growth 11.92%
Next Y EPS Growth 16.15% (at or above 15%: strong)
Next Y revenue growth 12.71% (at or above 10%: strong)
Next 5Y EPS Growth 17.15% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 2.1×; over the ten years it ranged from 0.5× in 2016 to 4.6× in 2025.
P/E against its own 10 years 10.91%
10-year low 10-year high
P/S against its own 10 years 81.98%
10-year low 10-year high
P/B against its own 10 years 82.16%
10-year low 10-year high
EV/Sales against its own 10 years 81.50%
10-year low 10-year high
EV/FCF against its own 10 years 45.98%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 7 16 15 20
Receivables 24 23 25 31
Inventory 4 4 3 4
Other 0 1 1 1
38 44 45 57
2023 2024 2025 2026
Payables 1 1 3 3
ST’ Debt — — — —
Other 3 2 3 4
8 8 10 12

Compound Annual Growth %

10y 5y 3y
Sales 12.37% 15.59% 15.35%
Cash Flow 16.13% 25.72% 94.43%
Earnings 17.71% 36.76% 52.83%
Book Value 12.68% 10.74% 12.74%

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 17 19 19 19 74
’25 15 16 16 17 64
’24 12 14 14 15 55
’23 11 12 12 14 48
’22 10 10 10 11 42
’21 8 9 9 9 36
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 0 3 3 3 10
’25 2 3 2 4 11
’24 0 3 1 4 9
’23 (2) 1 1 1 1
’22 (1) 0 0 (1) (1)
’21 1 1 1 1 3
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 0 2 3 3 8
’25 2 3 2 4 11
’24 0 3 1 4 9
’23 (2) 1 0 1 0
’22 (1) 0 0 (1) (2)
’21 1 1 1 1 3
Fiscal quarters ending in the months shown.

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 0.25 0.32 0.35 0.39 1.30
’25 0.16 0.22 0.21 0.25 0.85
’24 0.02 0.19 0.17 0.20 0.58
’23 0.01 0.11 0.12 0.12 0.36
’22 0.05 0.10 0.07 0.04 0.26
’21 0.06 0.13 0.03 0.04 0.27
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 3.68 4.60 4.75 6.92 8.98 8.75 8.80 9.81 17.73 23.01

Analyst estimates 2027–2029

Powerpack
High 7.96 7.33 10.99 19.73 13.85 13.46 13.84 31.31 35.56 47.40
People
People Employees 115 132 119 120 132 156 170 174 180 197
Revenue/emp, $m 0.22 0.21 0.26 0.27 0.27 0.27 0.28 0.31 0.36 0.37
Income, $m
Income, $m Revenue 26 28 31 32 36 42 48 55 64 74
Gross margin, % 79.53 76.92 76.19 77.61 76.36 75.47 75.98 76.26 78.08 78.54
EBT 4 3 3 5 3 3 4 7 10 14
EBT margin, % 13.61 9.65 9.33 16.13 8.86 7.19 8.50 12.86 16.07 19.46
Net income 2 2 2 4 2 2 3 5 8 11
Depreciation 1 1 1 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 3.17 3.45 3.77 3.86 4.17 4.92 5.68 6.39 7.57 8.93
Earnings 0.27 0.23 0.24 0.50 0.28 0.27 0.37 0.60 0.89 1.37
Cash flow 0.15 0.30 0.31 0.50 0.36 (0.08) 0.16 1.06 1.35 1.17
Capex (0.08) (0.07) (0.17) (0.12) (0.05) (0.18) (0.20) (0.05) (0.04) (0.16)
Free cash flow 0.06 0.23 0.14 0.38 0.31 (0.26) (0.05) 1.01 1.31 1.01
Book value 2.33 2.75 3.10 3.60 3.78 4.03 4.45 5.20 5.11 6.53
Shares, m 8 8 8 8 9 8 8 9 8 8
Valuation, ×
Valuation, × P/E 20.48 23.48 22.04 31.41 40.32 34.43 28.18 23.58 24.99 30.88
P/S 1.75 1.57 1.40 3.98 2.70 1.96 1.89 2.21 2.90 4.74
P/B 2.37 1.96 1.71 4.28 2.98 2.39 2.41 2.72 4.30 6.48
EV/Sales 1.58 1.38 1.19 3.70 2.40 1.79 1.76 1.94 2.68 4.48
EV/FCF 80.86 20.88 30.95 37.28 32.69 (33.76) (210.50) 12.25 15.49 39.49
Cash, $m
Cash, $m Operating cash flow 1 2 3 4 3 (1) 1 9 11 10
Capex (1) (1) (1) (1) 0 (2) (2) 0 0 (1)
Free cash flow 1 2 1 3 3 (2) 0 9 11 8
Balance, $m
Balance, $m Working capital 16 18 21 25 27 27 30 36 35 45
Total debt 1 1 0 0 0 0 0 — — —
Net debt (4) (6) (8) (10) (12) (8) (7) (16) (15) (20)
Shareholders’ equity 19 23 26 30 32 34 38 45 43 54
Returns, %
Returns, % ROA 10.22 7.26 6.97 13.28 6.71 5.87 7.26 10.51 14.22 18.82
ROIC 15.24 10.44 9.85 16.12 9.56 7.14 8.27 14.45 21.62 25.87
ROE 12.59 8.79 8.20 14.86 7.54 6.92 8.81 12.53 17.18 23.26
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Electromed, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
QSI Quantum-Si Incorporated $286.7M — (loss-making) — (loss-making) −41.79% (below 0%: shrinking) n/m +9.75% (above 0%: growing) 50.00% (7,450.29%) Compare
INFU InfuSystems Holdings, Inc. $277.2M 31.7× 21.7× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
TMCI Treace Medical Concepts, Inc. $267.9M — (loss-making) — (loss-making) −4.24% (below 0%: shrinking) n/m +11.74% (above 0%: growing) 78.47% (32.96%) Compare
CATX Perspective Therapeutics, Inc. $267.1M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%) Compare
LAB Standard BioTools Inc. $258.5M 2.9× — (loss-making) −7.62% (below 0%: shrinking) n/m +52.76% (above 0%: growing) 52.40% (126.28%) Compare
TLSI TriSalus Life Sciences, Inc. $240.1M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
ELMD Electromed, Inc. $232.3M 20.0× 25.5× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70%
PROF Profound Medical $230.5M — (loss-making) — (loss-making) +12.30% (above 0%: growing) n/m +17.51% (above 0%: growing) 78.41% (445.67%) Compare
RXST RxSight, Inc. $194.2M — (loss-making) — (loss-making) +0.31% (above 0%: growing) n/m −94.39% (below 0%: shrinking) 76.72% (40.81%) Compare
Median of peers $262.8M — — −1.96% — −15.77% 77.57% (106.15%)

All 149 Medical Devices stocks →

Electromed, Inc. (ELMD) key facts

  • Strength: Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025.
  • Electromed, Inc. (ELMD) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, ELMD traded at $27.42, a market capitalization of $232.3 million.
  • Return on equity was 23.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 20.30 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Electromed, Inc. (ELMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ELMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com